These medications were originally FDA-approved to treat Type 2 diabetes, then gained approval for weight management
Recent studies have shown patients taking GLP-1 medications are up to 68 times more likely to develop NAION and irreversible vision loss compared to those using other diabetes treatments, with over 140 cases now documented in the MDL
In male mice, gWAT undergoes the greatest expansion during HFD feeding and supports the bulk of lipogenesis during the active/feeding phase, placing a high demand on continuous NAD + -dependent tricarboxylic acid cycle (TCA) flux 21,49,50,51
Sjstedt P, Enander J, Isung J
Best of Oncology 2026 : GastroIntestinal Oncology
These changes prevent the quick breakdown that limits natural GLP-1 to a two-minute half-life